1. European Association of Urology Guidelines for Systemic Therapy in Metastatic Renal Cell Carcinoma: What is Recommended and Why? 
Jean-Jacques Patard 
European Urology Supplements 
Volume 7, Issue 2, Pages (February 2008)
DOI: /j.eursup
Copyright © 2007 European Association of Urology Terms and Conditions

2. Fig. 1
Progression-free survival by investigator assessment in the phase 2 studies of sunitinib as second-line therapy (pooled population, n=168) [15].
Copyright © 2006, American Medical Association. All rights reserved.
European Urology Supplements 2008 7, 46-54DOI: ( /j.eursup )
Copyright © 2007 European Association of Urology Terms and Conditions

3. Fig. 2
Effect of baseline factors on progression-free survival in the phase 3 trial of sunitinib versus interferon-α [16]. Data were missing for time since diagnosis for 15 patients and for haemoglobin level and corrected serum calcium for 16 patients. ECOG=Eastern Cooperative Oncology Group; LLN=lower limit of the normal range; ULN=upper limit of the normal range. Copyright © 2007 Massachusetts Medical Society. All rights reserved.
European Urology Supplements 2008 7, 46-54DOI: ( /j.eursup )
Copyright © 2007 European Association of Urology Terms and Conditions

4. Fig. 3
Kaplan-Meier estimates of (A) overall survival and (B) investigator-assessed progression-free survival among 903 patients in the phase 3 trial of second-line sorafenib versus interferon-α [24]. Panel A: p=0.02 for the comparison between the two study groups; threshold for statistical significance p=0.0005; panel B: p< Copyright © 2007 Massachusetts Medical Society. All rights reserved.
European Urology Supplements 2008 7, 46-54DOI: ( /j.eursup )
Copyright © 2007 European Association of Urology Terms and Conditions

5. Fig. 4
Kaplan-Meier estimates of (A) overall survival and (B) progression-free survival in the phase 3 study comparing temsirolimus with interferon-α (IFN-α) alone and temsirolimus in combination with IFN-α as first-line therapy in poor-risk patients [27]. Copyright © 2007 Massachusetts Medical Society. All rights reserved.
European Urology Supplements 2008 7, 46-54DOI: ( /j.eursup )
Copyright © 2007 European Association of Urology Terms and Conditions